In re application of:

# 10/552982

# JC05 Rec'd PCT/PTO 12 OCT 2005

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Melotto, S. et al.

	Serial No.:		To Be Assigned	Group Art Unit:					
	File Date:		Concurrently Herewith	Examiner:					
	For:		COMBINATIONS OF PAROXETINE AND 2-(R)-(4-FLUORO-2-METHYL-PHENYL)-4-(\$)-((8AS)-6-0XO-HEXAHYDRO-PYRROLO'1,2-A!-PYRAZIN-2-YL)-PIPERIDINE-1-CARBOXYLIC ACID'1-(R)-(3,5-BIS-TRIFLUOROMETHYL-PHENYL)-ETHYL!-METHYLAMIDE F. TREATMT. OF DEPRESSION/ANXIETY						
	P.O. Box 1		ent and Trademark Office		•				
INFORMATION DISCLOSURE STATEMENT									
Applicants request that the references identified on Form PTO-1449 appended hereto be considered Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97									
	[ ] Copies of the references are enclosed: [ ] Copies of the references were submitted in parent application								
	A. [X]	filing d applica	ate of the above application o	nt submitted herewith is being filed within three m or date of entry into the national stage of an internat e of a first Office action on the merits, whichever e	tional				
	[]	of a fir	formation Disclosure Staten st office action or after the f 1.114 (37 C.F.R. 1.97(b)(4))	nent submitted herewith is being filed before the filing of a Request For Continued Examination ).	e malling under 37				
	B. []	filing date of an internation event occur (1) a f	f the above application or the	,	1 § 1.491 ¢				
	[]	Statement w	as cited in a communication	of information contained in this Information Discle from a foreign patent office in a counterpart foreig rior to the filing of this statement.					
	[]		ects the option to pay the fee statement under § 1.97(c) (\$18	set forth in 37 CFR 1.17(p) for submission of an In 80.00).	formation				
	C. []	The Inform	ation Disclosure Statement tra	ansmitted herewith is being filed after a final actio .311, whichever occurs first, but before the payme	n under § nt of the				

issue fee. Also enclosed is a copy of the International Search Report which Issued on International

Publication No.

### JC05 Rec'd PCT/PTO 12 OCT 2005

## 10/552982

In accordance with the requirements of 37 CFR 1.97(d):

- [ ] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- Applicant hereby petitions for the consideration of the accompanying Information Disclosure Statement. 37 CFR 1.97(d)(ii).
- [] The petition fee set forth in § 1.17(i)(1) (\$130.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.
- [ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

Lorie Ann Morgan Registration No. 38,181

Date: /2 Oct 2005 GlaxoSmithKline

Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398
Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8222 Facsimile: (919) 483-7988

# JC05 Rec'd PCT/PTO 12 OCT 2005

			SERIAL NO.		To Be Ass	signed		
FORM PTO-144	19				Concurre	Concurrently Herewith Melotto et al.		
INFORMATION	N DISCLOSURE STA	TEMENT	FILING DAT		Melotto			
			APPLICANT	966	A P F A			
				GROUP 10/552982				
				ATTORNEY DOCKET NO. PB60212-3USW				
			TENT DOCUMENTS	DOCKET NO.	FB00212	30311		
		U.S. PA	TENT DOCUMENTS	T T		Filing Date		
Examiner Initials	Patent Number	Issue Date	Name	Class	Subclass	If Appropriate		
	US 2003/144270	July 31, 2003	Laci et al.					
	US 2002/123491	Sept. 5, 2003	Xiao et al.					
	US 2003/064980	Apr. 3, 2003	Xiao et al.					
	US 2004/014770	Jan. 22, 2004	Elvira et al.					
		Cor	ntinue on page					
			PATENT DOCUMEN	TS				
	Document	Publication				Translation Yes   No		
	Number	Date	Country	Class	Subclass	res   No		
	WO 02/10141	Feb. 7, 2002	WIPO					
	WO 01/44200	June 21, 2001	WIPO					
	WO 03/066635	Aug. 14, 2003	WIPO					
						<del> </del>		
			l					
		Co	ntinue on page	I Date Dans North	han Fta \			
	OTHER DOCUM	ENTS (Includin	g Author, Title, Journa	ii-Date, Page Nun	ber, Etc.)			
-								
		c	ontinue on page	DATE	CONSIDER	FD		
EXAMINER	/Renee Claytor/			0.9	/10/2009			
EXAMINER:	Initial if citation conside	red, whether or r	ot citation is in conforma	ance with MPEP §	609; Draw li	ne through		
citation if not it	n conformance and not c	onsidered. Inclu	de copy of this form with	next communicat	on to the app	licant.		

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /RC/